Literature DB >> 12224511

Avoiding proteasomal processing: the case of EBNA1.

N P Dantuma1, A Sharipo, M G Masucci.   

Abstract

Ubiquitin/proteasome-dependent proteolysis is involved in the regulation of a large variety of cellular processes including cell cycle progression, tissue development and atrophy, flux of substrates through metabolic pathways, selective elimination of abnormal proteins and processing of intracellular antigens for major histocompatibility complex (MHC) class I-restricted T-cell responses. Many viruses tamper with this proteolytic machinery by encoding proteins that interact with various components of the pathway. A particularly interesting example of a viral protein that interferes with proteasomal processing is the Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA1). EBNA1 contains an internal repeat exclusively composed of glycines and alanines that inhibits in cis the presentation of MHC class I-restricted T-cell epitopes and prevents ubiquitin/proteasome-dependent proteolysis in vitro and in vivo. The glycine-alanine repeat acts as a transferable element on a variety of proteasomal substrates and may therefore provide a new approach to the modification of cellular proteins for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224511     DOI: 10.1007/978-3-642-59421-2_2

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  12 in total

1.  Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing.

Authors:  Chrysoula Daskalogianni; Sébastien Apcher; Marco M Candeias; Nadia Naski; Fabien Calvo; Robin Fåhraeus
Journal:  J Biol Chem       Date:  2008-08-29       Impact factor: 5.157

Review 2.  Conserved and variable natural killer cell receptors: diverse approaches to viral infections.

Authors:  Leidy Y Bastidas-Legarda; Salim I Khakoo
Journal:  Immunology       Date:  2019-01-17       Impact factor: 7.397

Review 3.  Ubiquitin-independent proteasomal degradation during oncogenic viral infections.

Authors:  Jiwon Hwang; Laura Winkler; Robert F Kalejta
Journal:  Biochim Biophys Acta       Date:  2011-06-06

4.  Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Authors:  R Leskowitz; M H Fogg; X Y Zhou; A Kaur; E L V Silveira; F Villinger; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

5.  Immune regulation and evasion of Mammalian host cell immunity during viral infection.

Authors:  B M Pratheek; Soham Saha; Prasanta K Maiti; Soma Chattopadhyay; Subhasis Chattopadhyay
Journal:  Indian J Virol       Date:  2013-03-15

6.  Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells.

Authors:  Nick C Matthews; Martin R Goodier; Rebecca C Robey; Mark Bower; Frances M Gotch
Journal:  Eur J Immunol       Date:  2011-05-27       Impact factor: 5.532

Review 7.  Epstein-Barr virus latent genes.

Authors:  Myung-Soo Kang; Elliott Kieff
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

8.  CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.

Authors:  Steven P Lee; Jill M Brooks; Hatim Al-Jarrah; Wendy A Thomas; Tracey A Haigh; Graham S Taylor; Sibille Humme; Aloys Schepers; Wolfgang Hammerschmidt; John L Yates; Alan B Rickinson; Neil W Blake
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

Review 9.  Role of the ubiquitin system and tumor viruses in AIDS-related cancer.

Authors:  Julia Shackelford; Joseph S Pagano
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

10.  Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.

Authors:  Judy Tellam; Geoff Connolly; Katherine J Green; John J Miles; Denis J Moss; Scott R Burrows; Rajiv Khanna
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.